Skip to main content

Hypopara Newsroom

 

 

 

If you want to be in the know about what’s going on at our organization, you’ve come to the right place. Be sure to check back regularly to get our latest news updates.


AZP-3601 is currently in development for the treatment of hypoparathyroidism

Plans move forward with phase 3 PaTHway trial

The study will be conducted at the National Institutes of Health.

OCT 23 - 25. Live informative lectures on HypoPARA with knowledgeable doctors and specialists!

Working closely with physicians and care providers in managing hypoparathyroidism

Ongoing information about the future availability of the prescription parathyroid hormone

Celebrated internationally in recognition of all those with hypoparathyroidism